Greater improvements seen in glycemic control and weight loss than with high-carbohydrate, low-fat diet for persons with T2DM
MONDAY, Dec. 12, 2022 (HealthDay News) — For individuals with type 2 diabetes mellitus (T2DM), a six-month, calorie-unrestricted low-carbohydrate, high-fat (LCHF) diet results in greater improvements in glycemic control and weight loss than a high-carbohydrate, low-fat (HCLF) diet, according to a study published online Dec. 13 in the Annals of Internal Medicine.
Camilla Dalby Hansen, M.D., from the University of Southern Denmark in Odense, and colleagues conducted a six-month randomized controlled trial with a three-month follow-up to examine the effect of a calorie-unrestricted LCHF diet on T2DM and nonalcoholic fatty liver disease (NAFLD) among 165 participants with T2DM.
The researchers found that participants on the LCHF diet had greater improvements in hemoglobin A1c (mean difference in change, −0.59 percent) and lost more weight (mean difference in change, −3.8 kg) than those on the HCLF diet. At six months, both groups had higher high-density lipoprotein cholesterol and lower triglycerides. Compared with the HCLF group, changes in low-density lipoprotein cholesterol were less favorable in the LCHF group (mean difference in change, 14.3 mg/dL). In the assessment of NAFLD, there were no significant between-group changes noted. At the nine-month follow-up, changes were not sustained.
“Improvements were not sustained three months after the end of the intervention, suggesting the need for long-term dietary change to effect meaningful health benefits,” the authors write.
The study was partially funded by the Novo Nordisk Foundation.
Abstract/Full Text (subscription or payment may be required)
Weight-Loss Surgery Produces Lasting Diabetes Remission
Recommendations Issued for Use of Incretin-Based Meds in Pregnancy
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions